Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

Zhang, Yiran; Zhang, Meng; Jiang, Yifei; Li, Xiulian; He, Yong; Zeng, Pengjiao; Guo, Zhihua; Chang, Yajing; Luo, Heng; Liu, Yong; Hao, Cui; Wang, Hua; Zhang, Guoqing; Zhang, Lijuan

doi:10.1007/s00432-018-2718-1

Cited by 89 publications

(48 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Another meta-analysis including 3,117 patients of 38 RCTs in China showed an overall response rate in treating lung cancer treated with lentinanIV (1-1.5 mg/d, 2-8 weeks, depending on the study), a main ingredient of Lentinula edodes, was increased from 43.3% of chemotherapy alone to 56.9% of lentinan plus chemotherapy. Compared with chemotherapy alone, lentinan plus chemotherapy showed more efficacy in treating lung cancer (pooled RR 0.79, 95% CI: 0.74-0.85) (Zhang et al, 2018).…”

Section: Discussionmentioning

confidence: 99%

“…Many clinical studies have been conducted on the complementary use of these substances, e.g., in conjunction with chemotherapy. The results indicate relevant health benefits such as overall disease-free survival of colorectal cancer patients and in improving quality of life among lung cancer patients (Sakamoto et al, 2006;Zhang et al, 2018). A wide range of antitumoral or immunostimulating polysaccharides with different chemical structure from higher basidiomycetes mushrooms has been widely investigated (Wasser, 2002).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

Medicinal mushrooms are widely used in East Asia for the treatment of various diseases, especially in complementary cancer care. While there is a growing interest in medicinal mushrooms in Western countries and an increasing number of pre-clinical studies indicate distinct anti-cancer and regenerative properties, little is known about their potential relevance for clinical practice. This review aims to provide an overview of the clinical evidence, significance and potential role of medicinal mushrooms in complementary cancer care. Scientific databases for (randomized) controlled clinical trials evaluating whole spectrum formulations of medicinal mushrooms (mushroom powder and mushroom extracts) in cancer patients during and/or after conventional oncological treatment were searched. Eight studies met our inclusion criteria (eight randomized controlled trials, one controlled clinical trial). The medicinal mushrooms investigated were Agaricus sylvaticus (two trials), Agaricus blazei murill (two trials), Antrodia cinnamomea (one trial), Coriolus versicolor (one trial) and Ganoderma lucidum (three trials); all were compared to placebo and administered orally. A variety of cancer entities, outcomes and treatment durations were observed. Study results suggested beneficial effects of medicinal mushrooms, particularly quality of life and reduction of adverse effects of conventional therapies. Also, positive effects on antitumor activity and immunomodulation were reported, e.g., an increased activity of natural killer cells. In addition, results might suggest a longer survival of cancer patients receiving mushroom preparations, although in most studies this was not significant when compared to placebo. Adverse events of treatment with medicinal mushrooms were poorly reported; gastrointestinal reactions and a decrease in platelet cell count occurred in some cases. The methodological quality of most studies was generally unsatisfying and most results were insufficiently reported in several respects. Medicinal mushrooms may have a therapeutic potential for cancer patients during and after conventional oncological care with regards to quality of life, reduction of adverse effects of conventional care and possibly other surrogate parameters like immune function. There is an urgent need to investigate the safety and possible interactions of medicinal mushrooms. High-quality clinical research is warranted in order to clarify the potential of medicinal mushrooms in cancer therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The relatively inexpensive polysaccharides from the traditional Chinese herbs should be useable for the development of novel therapeutic agents, functional food, or adjuvants for preventing or treating different pathological conditions as those fungal polysaccharide-based drugs approved and used in China. 6,[121][122][123][124][125][126]…”

Section: Future Perspectivesmentioning

confidence: 99%

The structures and biological functions of polysaccharides from traditional Chinese herbs

Zeng

Chen

et al. 2019

Progress in Molecular Biology and Translational Science

Self Cite

249

121

View full text Add to dashboard Cite

Most of traditional Chinese medicine substances come from herbal plants. The medicinal quality of herbal plants varies with the locations of cultivation, the parts of the herb collected, the season of the herb collected, and the herb processing method. Polysaccharides are major components of the herb plants and their biosynthesis is partly controlled by the genes but mostly influenced by the availability of the nutrition and determined by the various environmental factors. In recent decades, polysaccharides isolated from different kinds of Chinese herbs have received much attention due to their important biological activities, such as anti-tumor, anti-oxidant, anti-diabetic, radiation protecting, antiviral, hypolipidemic, and immunomodulatory activities. Interestingly, different batches of the same herb can obtain different polysaccharide fractions with

show abstract

“…Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 86% of all new cases [2]. In China, NSCLC ranked as the first healthy menace, with an increasing incidence and mortality in most provinces, especially in Guangdong [3]. Although over the last couple of decades mounting progresses have been achieved in the early screening and clinical treatments for this tumor, the 5-year survival rate for patients with advanced stages remains below 18% due to those patients often exhibiting distant metastasis and recurrence, which results in frequent failures of various treatment methods [4,5].…”

Section: Introductionmentioning

confidence: 99%

STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis

Liu

Hao

et al. 2020

Aging

View full text Add to dashboard Cite

Several of the thousands of long noncoding RNAs (lncRNAs) have been functionally characterized in various tumors. In this study, we aimed to explore the function and possible molecular mechanism of lncRNA KTN1 antisense RNA 1 (KTN1-AS1) involved in non-small cell lung cancer (NSCLC). We identified a novel NSCLC-related lncRNA, KTN1 antisense RNA 1 (KTN1-AS1) which was demonstrated to be distinctly highly expressed in NSCLC. KTN1-AS1 upregulation was induced by STAT1. Clinical study also suggested that higher levels of KTN1-AS1 were associated with advanced clinical progression and a shorter five-year overall survival. Functionally, lossof-function assays with in vitro and in vivo experiments revealed that KTN1-AS1 promoted the proliferation, migration, invasion and EMT progress of NSCLC cells, and suppressed apoptosis. Mechanistic studies indicated that miR-23b was a direct target of KTN1-AS1, which functioned as a ceRNA to subsequently facilitate miR-23b's target gene DEPDC1 expression in NSCLC cells. Rescue experiments confirmed that KTN1-AS1 overexpression could increase the colony formation and migration ability suppressed by miR-23b upregulation in NSCLC cells. Overall, our findings imply that STAT1-induced upregulation of KTN1-AS1 display tumor-promotive roles in NSCLC progression via regulating miR-23b/DEPDC1 axis, suggesting that KTN1-AS1 may be a novel biomarker and therapeutic target for NSCLC patients.

show abstract

Lentinan as an immunotherapeutic for treating lung cancer: a review of 12 years clinical studies in China

Abstract: Clinical data presented in the past 12 years shows that lentinan is effective not only in improving quality of life, but also in promoting the efficacy of chemotherapy during lung cancer treatment.

Cited by 89 publications

References 44 publications

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

Significance of Medicinal Mushrooms in Integrative Oncology: A Narrative Review

The structures and biological functions of polysaccharides from traditional Chinese herbs

STAT1-induced upregulation of lncRNA KTN1-AS1 predicts poor prognosis and facilitates non-small cell lung cancer progression via miR-23b/DEPDC1 axis

Contact Info

Product

Resources

About